Scholarlink

Purpose of Review <p>Rabbit anti-thymocyte globulin (rATG) is a key agent in induction immunosuppression for kidney transplantation, yet its optimal dosing strategy remains controversial. This review evaluates recent data to assess the impact of various dosing regimens on efficacy, safety, and cost-effectiveness.</p> Recent Findings <p>Lower cumulative doses of rATG may reduce infection rates and hematologic toxicity without compromising efficacy. In contrast, higher doses, while more effective at preventing rejection, are associated with an increased risk of infectious complications. Single-dose administration offers logistical and economic advantages, whereas multi-dose regimens provide sustained T-cell depletion, which may benefit high-risk recipients. Individualized dosing strategies—such as using ideal body weight—have proven effective in both obese and non-obese patients. Pediatric patients generally require lower cumulative doses. Emerging evidence supports biomarker-guided intermittent dosing to optimize drug exposure and reduce adverse effects.</p> Summary <p>Although variability in existing data limits the formulation of universal guidelines, evidence supports the adoption of individualized approaches. These include immunologic risk stratification, pharmacokinetic modeling, biomarker-guided strategies, and practical dosing logistics. Future prospective studies are critical to validate and standardize these approaches, ensuring safe, effective, and economically sustainable use of rATG in kidney transplantation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thymoglobulin Dosing for Induction in Kidney Transplant Recipients: A Systematic Review

  • 期刊论文

  • 发表日期：

    2025年4月25日

查看全文
  • Bassem A. Almalki,
  • Mutlaq Alotaibi,
  • Mesfer Alghamdi,
  • Sara Abdullatif Albilal,
  • Ibrahim M. Asiri,
  • Othman Jamal Allail,
  • Fatimah Bukhamseen,
  • Manal Alotaibi

摘要

Purpose of Review

Rabbit anti-thymocyte globulin (rATG) is a key agent in induction immunosuppression for kidney transplantation, yet its optimal dosing strategy remains controversial. This review evaluates recent data to assess the impact of various dosing regimens on efficacy, safety, and cost-effectiveness.

Recent Findings

Lower cumulative doses of rATG may reduce infection rates and hematologic toxicity without compromising efficacy. In contrast, higher doses, while more effective at preventing rejection, are associated with an increased risk of infectious complications. Single-dose administration offers logistical and economic advantages, whereas multi-dose regimens provide sustained T-cell depletion, which may benefit high-risk recipients. Individualized dosing strategies—such as using ideal body weight—have proven effective in both obese and non-obese patients. Pediatric patients generally require lower cumulative doses. Emerging evidence supports biomarker-guided intermittent dosing to optimize drug exposure and reduce adverse effects.

Summary

Although variability in existing data limits the formulation of universal guidelines, evidence supports the adoption of individualized approaches. These include immunologic risk stratification, pharmacokinetic modeling, biomarker-guided strategies, and practical dosing logistics. Future prospective studies are critical to validate and standardize these approaches, ensuring safe, effective, and economically sustainable use of rATG in kidney transplantation.